LENSAR, Inc. (LNSR)
Pre-market:
| Previous close | 3.9700 |
| Open | 4.0600 |
| Bid | 3.9500 x 100 |
| Ask | 0.0000 x 0 |
| Day's range | 3.9950 - 4.3199 |
| 52-week range | 1.8000 - 5.3000 |
| Volume | |
| Avg. volume | 43,819 |
| Market cap | 47.298M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
LENSAR to Participate in the 2024 Leerink Partners Healthcare Crossroads Conference
ORLANDO, Fla., May 23, 2024--LENSAR, Inc. (Nasdaq: LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of cataracts, today announced that Nick Curtis, Chief Executive Officer, will participate in a Fireside Chat at the 2024 Leerink Partners Healthcare Crossroads Conference on Wednesday, May 29, 2024, at 1:40 p.m. CT in Austin, TX.
- Business Wire
LENSAR Reports First Quarter 2024 Results and Provides Business Update
ORLANDO, Fla., May 09, 2024--LENSAR, Inc. (Nasdaq: LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of cataracts, today announced financial results for the quarter ended March 31, 2024 and provided an update on key operational initiatives.
- Business Wire
LENSAR to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
ORLANDO, Fla., May 02, 2024--LENSAR, Inc. (Nasdaq: LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of cataracts, today announced that the Company’s first quarter 2024 financial results will be released before market open on Thursday, May 9, 2024. LENSAR’s management will host a conference call and webcast at 8:30 am ET on Thursday, May 9, 2024 to discuss the financial results and recent corporate highlights.
